This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Satsuma Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
Satsuma Pharmaceuticals' CEO is John Kollins, appointed in Jul 2016, he has a tenure of 6.92 years. His total yearly compensation is $1.91M , comprised of 27.8% salary and 72.2% bonuses, including company stock and options. He directly owns 0.94% of the company’s shares, worth €317.23K. The average tenure of the management team and the board of directors is 5.9 years and 5.8 years respectively.
Belangrijke informatie
John Kollins
Algemeen directeur
US$1.9m
Totale compensatie
| Percentage CEO-salaris | 27.8% |
| Dienstverband CEO | 6.9yrs |
| Eigendom CEO | 0.9% |
| Management gemiddelde ambtstermijn | 5.9yrs |
| Gemiddelde ambtstermijn bestuur | 5.8yrs |
Recente managementupdates
Recent updates
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$65m |
| Dec 31 2022 | US$2m | US$530k | -US$70m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$61m |
| Mar 31 2022 | n/a | n/a | -US$56m |
| Dec 31 2021 | US$830k | US$500k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$4m | US$456k | -US$48m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$1m | US$391k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$20m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$568k | US$362k | -US$7m |
Compensatie versus markt: John's total compensation ($USD1.91M) is above average for companies of similar size in the German market ($USD407.72K).
Compensatie versus inkomsten: John's compensation has increased whilst the company is unprofitable.
CEO
John Kollins (60 yo)
6.9yrs
Tenure
US$1,909,812
Compensatie
Mr. John A. Kollins, MBA, has been Director, President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc since July 2016. He served as Chief Business Officer and Senior Vice President of Transcep...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 6.9yrs | US$1.91m | 0.94% € 317.2k | |
| Chief Financial Officer | 4.4yrs | US$936.85k | 0.042% € 14.2k | |
| VP & Head of Operations | 6.4yrs | geen gegevens | geen gegevens | |
| Senior VP & Head of Chemistry | 5.9yrs | geen gegevens | geen gegevens | |
| VP & Head of Regulatory Affairs | 5.1yrs | geen gegevens | geen gegevens |
5.9yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: 1LV's management team is seasoned and experienced (5.9 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 6.9yrs | US$1.91m | 0.94% € 317.2k | |
| Independent Director | 2.9yrs | US$132.08k | 0% € 0 | |
| Independent Director | 5.8yrs | US$131.58k | 0% € 0 | |
| Independent Chairman of the Board | 6.5yrs | US$160.08k | 0% € 0 | |
| Independent Director | 6.5yrs | US$120.58k | 0% € 0 | |
| Independent Director | 1.7yrs | US$124.58k | 0% € 0 | |
| Independent Director | 7yrs | US$124.08k | 0% € 0 | |
| Independent Director | 4.1yrs | US$132.08k | 0% € 0 | |
| Independent Director | 5.7yrs | US$126.08k | 0% € 0 |
5.8yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: 1LV's board of directors are considered experienced (5.8 years average tenure).